These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 29462947)

  • 1. Immunogenic Apoptosis as a Novel Tool for Anticancer Vaccine Development.
    Montico B; Nigro A; Casolaro V; Dal Col J
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Dendritic Cell-Based Vaccination Protocol to Stimulate Immunosurveillance of Aggressive Cancers.
    Nigro A; Montico B; Casolaro V; Dal Col J
    Methods Mol Biol; 2019; 1884():317-333. PubMed ID: 30465213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma.
    Garg AD; Vandenberk L; Koks C; Verschuere T; Boon L; Van Gool SW; Agostinis P
    Sci Transl Med; 2016 Mar; 8(328):328ra27. PubMed ID: 26936504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal.
    Garg AD; Elsen S; Krysko DV; Vandenabeele P; de Witte P; Agostinis P
    Oncotarget; 2015 Sep; 6(29):26841-60. PubMed ID: 26314964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor cell lysates as immunogenic sources for cancer vaccine design.
    González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F
    Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.
    Zappasodi R; Pupa SM; Ghedini GC; Bongarzone I; Magni M; Cabras AD; Colombo MP; Carlo-Stella C; Gianni AM; Di Nicola M
    Cancer Res; 2010 Nov; 70(22):9062-72. PubMed ID: 20884630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenic cell death-based cancer vaccines: promising prospect in cancer therapy.
    Wang J; Ma J; Xie F; Miao F; Lv L; Huang Y; Zhang X; Yu J; Tai Z; Zhu Q; Bao L
    Front Immunol; 2024; 15():1389173. PubMed ID: 38745666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gold Standard Assessment of Immunogenic Cell Death in Oncological Mouse Models.
    Humeau J; Lévesque S; Kroemer G; Pol JG
    Methods Mol Biol; 2019; 1884():297-315. PubMed ID: 30465212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shikonin-enhanced cell immunogenicity of tumor vaccine is mediated by the differential effects of DAMP components.
    Lin TJ; Lin HT; Chang WT; Mitapalli S P; Hsiao PW; Yin SY; Yang NS
    Mol Cancer; 2015 Sep; 14():174. PubMed ID: 26403780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenic cancer cell death: a key-lock paradigm.
    Tesniere A; Apetoh L; Ghiringhelli F; Joza N; Panaretakis T; Kepp O; Schlemmer F; Zitvogel L; Kroemer G
    Curr Opin Immunol; 2008 Oct; 20(5):504-11. PubMed ID: 18573340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing dendritic cells in cancer.
    Apetoh L; Locher C; Ghiringhelli F; Kroemer G; Zitvogel L
    Semin Immunol; 2011 Feb; 23(1):42-9. PubMed ID: 21295491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenic cell death in cancer therapy: Present and emerging inducers.
    Zhou J; Wang G; Chen Y; Wang H; Hua Y; Cai Z
    J Cell Mol Med; 2019 Aug; 23(8):4854-4865. PubMed ID: 31210425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High hydrostatic pressure induces immunogenic cell death in human tumor cells.
    Fucikova J; Moserova I; Truxova I; Hermanova I; Vancurova I; Partlova S; Fialova A; Sojka L; Cartron PF; Houska M; Rob L; Bartunkova J; Spisek R
    Int J Cancer; 2014 Sep; 135(5):1165-77. PubMed ID: 24500981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stress-induced cellular responses in immunogenic cell death: Implications for cancer immunotherapy.
    Radogna F; Diederich M
    Biochem Pharmacol; 2018 Jul; 153():12-23. PubMed ID: 29438676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy.
    Adkins I; Fucikova J; Garg AD; Agostinis P; Špíšek R
    Oncoimmunology; 2014 Dec; 3(12):e968434. PubMed ID: 25964865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses.
    Garg AD; Agostinis P
    Immunol Rev; 2017 Nov; 280(1):126-148. PubMed ID: 29027218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenic cell death.
    Garg AD; Dudek-Peric AM; Romano E; Agostinis P
    Int J Dev Biol; 2015; 59(1-3):131-40. PubMed ID: 26374534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunogenicity of tumor cell death.
    Kepp O; Tesniere A; Zitvogel L; Kroemer G
    Curr Opin Oncol; 2009 Jan; 21(1):71-6. PubMed ID: 19125021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of DC vaccine with ALA-PDT induced immunogenic apoptotic cells for skin squamous cell carcinoma.
    Ji J; Fan Z; Zhou F; Wang X; Shi L; Zhang H; Wang P; Yang D; Zhang L; Chen WR; Wang X
    Oncotarget; 2015 Jul; 6(19):17135-46. PubMed ID: 25915530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A vaccine for photodynamic immunogenic cell death: tumor cell caged by cellular disulfide-thiol exchange for immunotherapy.
    Wen Y; Liu Y; Guo F; Han Y; Qiu Q; Li Y; Dong H; Ren T; Li Y
    Biomater Sci; 2021 Feb; 9(3):973-984. PubMed ID: 33300512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.